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DETERMINING DISEASE CAUSALITY
FROM EXPERIMENTAL TOXICOLOGY
STUDIES
Ronald L. Melnick, Ph.D. and
John R. Bucher, Ph.D.∗
INTRODUCTION
In contrast to attempts by journals and scientific review
panels to reveal and/or limit conflicts of interest in scientific
publications and peer review evaluations,1 conflicts of interest
are an inherent component of science-based litigation, and
generally include presentations and interpretations of studies that
are fashioned to appear consistent and favorable to the position
of the sponsoring party.2 This situation puts an enormous burden
on judges and juries, forcing them to wade through disguised
biases in order to decipher assertions from facts. Numerous
conflicts have and continue to arise over the reliability and
interpretation of health effects research data because of
uncertainties in the precise extrapolation of adverse effects
observed in experimental animals to individual human risk and
in the costs and benefits associated with reduction or elimination
∗

Ronald L. Melnick is Director of Special Programs, Environmental
Toxicology Program (ETP), National Toxicology Program (NTP), National
Institute of Environmental Health Sciences (NIEHS); John R. Bucher is
Deputy Director ETP, NTP/NIEHS.
1
See, e.g., Frank Davidoff et al., Sponsorship, Authorship, and
Accountability, 345 N. ENG. J. MED. 825, 825-27 (2001); Vincent James
Cogliano et al., The Science and Practice of Carcinogen Identification and
Evaluation, 112 ENVTL. HEALTH PERSP. 1269, 1269-74 (2004).
2
See, e.g., Wendy Wagner, The Perils of Relying on Interested Parties
to Evaluate Scientific Quality. 95 Am. J. Pub. Health S99, S99-S106 (2005).
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of human exposures to toxic agents.3 Conflicting opinions on the
utility of data obtained from studies in laboratory animals seem
to originate largely from concerns of impacts of exposures on
human health versus impacts on costs and profits.4
Although science seeks to expand our knowledge of facts and
truths through the principles of hypothesis generation and
hypothesis testing, the way in which our knowledge grows and
reflects the truth depends on how questions are framed, how
rigorously hypotheses are tested, and to what extent assertions
extend beyond actual findings and are portrayed as established
facts. This paper focuses on principles of design and evaluation
of animal carcinogenicity studies and the utility of these studies
for determining disease causality and estimating human cancer
risk. Part I will discuss the use of animal studies in the context
of public health decisions. Part II will examine issues concerning
the design of experimental studies. Part III will explore issues
relating to how experimental studies are evaluated and Part IV
will explore issues concerning the assessment of human cancer
risk based on results from animal experimentation.
I. USE OF ANIMAL STUDIES FOR PUBLIC HEALTH DECISIONS
In 1978, the Department of Health Education and Welfare
(now the Department of Health and Human Services) created the
National Toxicology Program (NTP), an interagency resource to
coordinate toxicology testing programs within the federal
government.5 The mission of the NTP is to strengthen the
scientific basis for risk assessments, develop and validate
improved testing methods, and provide information about
potentially toxic chemicals to health, regulatory, and research
3

Ronald L. Melnick, A Daubert Motion–A Legal Strategy to Exclude
Essential Scientific Evidence in Toxic Tort Litigation, 95 Am. J. Pub. Health
S30, S30-S34 (2005).
4
Laura Heinzerling & Frank Ackerman, Pricing the Priceless: CostBenefit Analysis of Environmental Protection, GEO. ENVTL. L & POL’Y INST.,
GEO. U.L. CENTER (2002).
5
J.A. Califano, Establishment of a National Toxicology Program,
Federal Reg. 43, 53080-53081 (1978).
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agencies, the scientific and medical communities, and the
public.6 Since the time of its inception, more than 600 agents
have been tested for carcinogenic activity in laboratory animals,
and technical reports of those studies have undergone peer
review.7 The standardized approaches used by the NTP for the
evaluation of carcinogenicity of environmental and occupational
agents are frequently referred to as the gold standard for
carcinogen identification.8 Congress also mandates that the NTP
provide and update a list of substances that are “reasonably
anticipated” or “known” human carcinogens.9 Currently, the
NTP’s Eleventh Report on Carcinogens lists 246 agents under
one of these two categories.10
Why are animal models used to evaluate human risk? The
most obvious explanation is that it is unethical to test for adverse
health effects, such as cancer, in humans through intentional
exposures.11 Just as animal models are used in preclinical trials
of new pharmaceutical agents before testing in humans,
experimental studies performed on animals have been used to
assess potential health risks of toxic and carcinogenic agents in
our workplace and general environment.12 The predictive value
of animal studies is based on species similarities in the biological
processes of disease induction.13 Another major advantage of
6

Id.
See Department of Health and Human Services, The National
Toxicology Program, http://ntp.niehs.nih.gov (listing toxicology studies).
8
John R. Bucher, The National Toxicology Program Rodent Bioassay:
Designs, Interpretations and Scientific Contributions, Annals N.Y. Acad. Sci.
982, 198-207 (2002).
9
Public Health Services Act, 42 U.S.C. § 241(b)(4) (1999).
10
NAT’L TOXICOLOGY PROGRAM, U.S. DEPARTMENT OF HEALTH AND
HUMAN SERVICES, REPORT ON CARCINOGENS at I-5 (11th ed. 2004).
11
C. Oleskey et al., Pesticide Testing in Humans: Ethics and Public
Policy, 112 ENVTL. HEALTH PERSP. 914, 914-19 (2004).
12
See Environmental Protection Agency, IRIS Database for Risk
Assessment, available at http://www.epa.gov/iris (containing a database of
toxicology studies).
13
H.R. Pohl et al., Risk Assessment of Chemicals and Pharmaceuticals
in the Pediatric Population: A Workshop Report, 42 REGULATORY
TOXICOLOGY & PHARMACOLOGY 83, 83-95 (2005); I.H. Russo & J. Russo,
7
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animal studies is the elimination of the need to wait for a high
incidence of human cancers, which may take as much as 30
years from time of first exposure to clinical manifestation of
disease, before implementing public health protective
strategies.14
Human epidemiology studies typically have limited exposure
information especially at times early in tumor development, and
confounding factors are not always known.15 In contrast,
exposure conditions can be finely controlled in experimental
studies, making it easier to interpret and assign causality.16 The
major disadvantages of animal studies are that they require
extrapolations across species and dose, and they do not capture
the full range of human susceptibility due to differences in
genetics, health status, diet, life style, and exposures to other
agents.17
Public health agencies, including the International Agency
for Research on Cancer (IARC),18 NTP,19 and the U.S.
Environmental Protection Agency (EPA),20 have endorsed the
perspective that “in the absence of adequate data in humans, it is
Mammary Gland Neoplasia in Long-Term Rodent Studies, 104 ENVTL.
HEALTH PERSP. 938, 938-67 (1996).
14
See World Health Organization International Agency for Research on
Cancer, IARC Monographs on the Evaluation of Carcinogenic Risks to
Humans, at 14, available at http://monographs.iarc.fr/ENG/Preamble/
CurrentPreamble.pdf (last visited Dec. 14, 2006).
15
L.T. Stayner & R.J. Smith, Methodologic Issues in Using
Epidemiologic Studies of Occupational Cohorts for Cancer Risk Assessment,
14 EPIDEMIOL. PREV. 32, 32-39 (1992).
16
L. Tomatis, Role of Experimental and Epidemiological Evidence of
Carcinogenicity in the Primary Prevention of Cancer, 42 ANNALI
DELL’ISTITUTO SUPERIORE DI SANITÀ 113, 113-17 (2006) (Italy).
17
R.J. Preston, Extrapolations are the Achilles Heel of Risk Assessment,
589 MUTATION RESEARCH 153, 153-57 (2005).
18
77 INT’L AGENCY FOR RESEARCH ON CANCER, Di(2ethylhexyl)phthalate, in IARC MONOGRAPHS ON THE EVALUATION OF
CARCINOGENIC RISKS TO HUMANS 41-148 (2000).
19
NAT’L TOXICOLOGY PROGRAM, supra note 10.
20
U.S. ENVTL. PROT. AGENCY, PUBL’N NO. EPA/630/P-03/001F,
GUIDELINES FOR CARCINOGEN RISK ASSESSMENT (2005).
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biologically plausible and prudent to regard agents and mixtures
for which there is sufficient evidence of carcinogenicity in
experimental animals as if they presented a carcinogenic risk to
humans.” This position is based on the fact that all known
human carcinogens that have been studied adequately in
experimental animals produce positive carcinogenic results.21
Hence, even in the absence of adequate human data, public
health agencies have classified agents as possibly/probably or
likely to be carcinogenic to humans22 or reasonably anticipated
to be a human carcinogen23 if there is sufficient evidence in
animals demonstrating either (1) increased incidence of
malignant or malignant and benign tumors combined in two or
more species or at multiple sites, or (2) increased incidence in
two or more independent studies in one species, or (3) increased
incidence in a single study in one species if malignant tumors
occur to an unusual degree in incidence, site, type, or age of
onset.24 Several agents that were considered to be possible or
probable human carcinogens based on animal data were later
confirmed as human carcinogens when reliable epidemiology
data (usually occupational exposures) became available (e.g.,
1,3-butadiene, cadmium, diethylstilbestrol, ethylene oxide,
formaldehyde, and vinyl chloride).25

21

INT’L AGENCY FOR RESEARCH ON CANCER, supra note 18.
INT’L AGENCY FOR RESEARCH ON CANCER, supra note 18; U.S.
ENVTL. PROT. AGENCY, supra note 20.
23
NAT’L TOXICOLOGY PROGRAM, supra note 10.
24
INT’L AGENCY FOR RESEARCH ON CANCER, supra note 18; NATIONAL
TOXICOLOGY PROGRAM, supra note 10; U.S. ENVTL. PROT. AGENCY, supra
note 20.
25
James Huff, Chemicals and Cancer in Humans: First Evidence in
Experimental Animals, 100 ENVTL. HEALTH PERSP. 201 (1993), available at
http://www.pubmedcentral.com/picrender.fcgi?artid=1519590&blobtype=pdf
(last visited Nov. 29, 2006)
22
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II. EXPERIMENTAL DESIGN ISSUES
The design of experimental studies is critical for the
identification of adverse health effects caused by specific
environmental agents and the characterization of dose-response
relationships.26 For example, deficiencies in early studies of
benzene in animals, which included too few animals, lack of
controls, short study duration, and low levels of exposure, failed
to detect carcinogenic effects, even though epidemiology studies
had demonstrated a causal association between benzene exposure
and leukemia in humans. Subsequent studies that were better
designed established benzene as a potent, multi-site carcinogen
in rats and mice.27
Experimental design issues that might influence the outcome
of a carcinogenicity study in laboratory animals are discussed
below and include the purity and stability of the chemical agent,
the animal models used, the number of animals per dose group,
and the exposure levels.
A. Chemical
To ensure that the agent under study is responsible for any
observed effects and that any contaminants are not the cause or
modifier of that response, the chemical should be tested at high
purity. Prior to exposing animals to the agent, it is necessary to
demonstrate its stability under the conditions of exposure and
storage. If the agent degrades or evaporates during exposure, the
accuracy of the targeted administered dose is compromised and
26

See Bucher, supra note 8.
Cesare Maltoni et al., Benzene, an Experimental Multipotential
Carcinogen: Results of the Long-Term Bioassays Performed at the Bologna
Institute of Oncology, 82 ENVTL. HEALTH PERSP. 109 (1989), available at
http://www.pubmedcentral.com/picrender.fcgi?artid=1568122&blobtype=pdf
(last visited Nov. 29, 2006); J.E. Huff et al., Multiple-Site Carcinogenicity of
Benzene in Fischer 344 Rats and B6C3F1 Mice, 82 ENVTL. HEALTH PERSP.
125
(1989),
available
at
http://www.pubmedcentral.com/
picrender.fcgi?artid=1568117&blobtype=pdf (last visited Nov. 29, 2006).
27
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degradation products may contribute to any observed response.
For example, a study of trichloroethylene mixed in feed would
not have reliable exposure data due to the volatile loss of this
chemical from the feed samples and the potential cross
contamination of the control groups by inhalation exposure.
B. Animal Models
Rats and mice are the two species most frequently used in
tests for carcinogenic activity because they have life spans of
about two-and-a-half years28 and studies of up to 1,000 animals
can be performed in reasonably sized animal rooms. Strains of
animal models used should have good longevity, genetic
stability, and few spontaneous diseases that might shorten their
life span, mask any chemical induced effects, or impair
metabolism/elimination of the test agent.29 It is difficult to detect
a chemically induced response in an organ with a high
spontaneous tumor rate.30 Both sexes of two species are typically
used to identify any sex-specific responses and to confirm
multiple species effects.31
A major shortcoming of the rodent cancer bioassay is its
limited statistical power to estimate the true response rate.32
Power is the probability of detecting an effect (rejecting the null
hypothesis33) when an effect exists; it is influenced by the
28

H.A. Solleveld et al., Natural History of Body Weight Gain, Survival,
and Neoplasia in the F344 Rat, 72 J. NATL. CANCER INST., 929-40 (1984).
29
G.N. Rao et al., Mouse Strains for Chemical Carcinogenicity Studies:
Overview of a Workshop, 10 FUNDAMENTALS OF APPLIED TOXICOLOGY 385,
385-94 (1988).
30
Helmut Greim et al., Evaluation of Historical Control Data in
Carcinogenicity Studies, 22 HUM. EXP. TOXICOL. 541, 541-49 (2003).
31
See Bucher, supra note 8.
32
Joseph K. Haseman, Statistical Support of the Proposed National
Toxicology Program Protocol, 11 TOXICOLOGICAL PATHOLOGY 77, 77-82
(1983).
33
In this case, the null hypothesis is that there is no difference in
response between exposed and unexposed animals. Rejection of the null
hypothesis implies that an alternative hypothesis is more appropriate (i.e., the
response is different in exposed versus unexposed animals).
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sample size, the background rate, and the magnitude of the true
response.34 For example, in order to achieve statistical
significance at the p≤0.05 level (i.e., the odds are 1 in 20 or less
that a result occurred simply by chance) in a bioassay consisting
of about 50 animals per sex and species per dose group, an
incidence of 14 percent (7/50) or greater would be necessary in
the exposed group if the incidence in the control group was two
percent (1/50). Likewise, if the control incidence is 20 percent
(10/50), the incidence in the treated group would need to be 38
percent or greater (19/50) to achieve statistical significance at
p≤0.05. However, if animal group size were only 25, then an
incidence of 40 percent (10/25) would not be significant if the
control incidence was still 20 percent (5/25). The power
limitation of a study may lead to conflicting opinions when no
changes or non-significant elevations in incidence are detected in
treatment groups of small size. If the null hypothesis is not true
(i.e., exposure produces an effect), the power of the study
should be sufficiently large to allow rejection of that hypothesis.
A negative, underpowered study provides no assurance of the
absence of health risks in exposed populations.
C. Exposure
Because of the limited statistical power of the bioassay when
group size is only about 50 animals per sex per dose, high doses
are typically used to identify potential carcinogenic hazards and
multiple dose-groups are used to characterize dose-response
relationships.35 Unless group size is extremely large (i.e.,
several hundred to thousands of animals per group), a negative
carcinogenicity study (no statistically significant exposure-related
effects) conducted at environmental exposure levels can lead to
misinterpretation of the carcinogenic potential of an agent. For
34

Joseph K. Haseman, Statistical Issues in the Design, Analysis and
Interpretation of Animal Carcinogenicity Studies, 58 ENVTL. HEALTH PERSP.
385, 385-92 (1984).
35
Richard A. Griesemer, Dose Selection for Animal Carcinogenicity
Studies: A Practitioner’s Perspective, 5 CHEM. RES. TOXICOL. 737, 737-41
(1992); Bucher, supra note 8.
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example, if the true response rate at an environmental exposure
level is 1 per 1000, then this exposure would not reveal a
significant response if the animal group size is 50. However,
environmental exposures associated with increased cancer risk of
1 per 1000 in human populations would be dreadful. Data from
preliminary studies, typically of 4 to 13 weeks duration,
including evaluations of body weight changes, clinical
observations, and pathological effects are used to estimate the
maximally tolerated dose or the minimally toxic dose (MTD) for
the subsequent cancer study.36
The identification and use of an MTD is a critical aspect in
the design of experimental carcinogenicity studies of low
statistical power.37 The MTD should not cause increases in
mortality other than from chemically induced tumors. Lower
doses (one-half MTD and one-quarter to one-tenth MTD) are
used if the high dose selected for the chronic study is found to
be too high (excessive mortality) and to provide dose-response
information.38 Pharmacokinetic information is also used to
ensure that no more than one of the selected doses is above a
level that saturates the processes of absorption, metabolic
activation, or detoxification.39 In the absence of human data, the
dose-response relationship in an experimental animal study
serves as the basis for estimating risks at human exposure
levels.40 A much better characterization of the true doseresponse can be achieved with several dose groups rather than
36

Victor A. Fung et al., The Carcinogenesis Bioassay in Perspective:
Application in Identifying Human Cancer Hazards, 103 ENVTL. HEALTH
PERSP. 680, 680-83 (1995).
37
C.J. Portier & D.G. Hoel, Design of Animal Carcinogenicity Studies
for Goodness-of-Fit of Multistage Models, 4 FUNDAMENTALS OF APPLIED
TOXICOLOGY 949, 949-59 (1984).
38
John R. Bucher et al., Workshop Overview, National Toxicology
Program Studies: Principles of Dose Selection and Applications to
Mechanistic Based Risk Assessment, 31 FUNDAMENTALS OF APPLIED
TOXICOLOGY 1, 108 (1996).
39
J.R. Buchanan et al., Purpose and Guidelines for Toxicokinetic Studies
Within the National Toxicology Program, 105 ENVTL. HEALTH PERSP. 468,
468-71 (1997).
40
U.S. ENVTL. PROT. AGENCY, supra note 20.
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only two widely spaced dose groups.
Typical carcinogenicity studies in rats and mice involve
exposures beginning at six weeks of age and continuing for two
years; this exposure period corresponds roughly with early
adulthood through most of an occupational life span.41 However,
because of data indicating greater susceptibility with exposure to
mutagens42 and endocrine disruptors43 during growth and early
developmental stages, earlier periods of exposure are frequently
included in animal carcinogenicity studies when fetal or
childhood exposure to such agents might occur. The two-year
duration limit was selected to minimize late-developing
background tumor responses in controls as well as in animals
exposed to the test agent that might preclude the detection of
chemical-induced effects.44 Studies with exposure durations
shorter than two years are also problematic because of their
reduced sensitivity to detect increases in late-appearing tumors
that are related to treatment with the test agent.45
III. EVALUATION ISSUES
The conduct and evaluation of a cancer bioassay requires a
multidisciplinary effort, including expertise from toxicologists,
laboratory animal veterinarians, chemists, histologists,
pathologists, cellular/molecular biologists, and statisticians. The
interpretation of tumor data may be affected by the thoroughness
of the histopathology evaluations, methods of statistical analysis,
41

Joseph K. Haseman et al., Carcinogenesis Bioassays: Study Duration
and Biological Relevance, 39 FOOD & CHEMICAL TOXICOLOGY 739, 739-44
(2001).
42
J. M. Rice et al., Comparative Transplacental Carcinogenesis by
Directly Acting and Metabolism-dependent Alkylating Agents in Rodents and
Nonhuman Primates, 96 IARC SCI. PUBL. 17, 17-34 (1989).
43
A.L. Herbst et al., Prenatal Diethylstilbestrol Exposure and Human
Genital Tract Abnormalities, 51 NAT’L CANCER INST. MONOGRAPH 25, 25-35
(1979). An endocrine disruptor is a natural or synthetic chemical that may
mimic or antagonize the actions of natural hormones responsible for
maintaining homeostasis and regulating development.
44
Solleveld, supra note 28.
45
Haseman, supra note 41.
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and mechanistic considerations. With respect to human relevance
of animal cancer data, the issue of concordance of the site of
occurrence of the tumor has been raised; this topic is also
discussed below.
A. Histopathology
The detection of toxic effects and neoplastic lesions in
animals depends on the thoroughness of the necropsies, or postmortem examinations of the animal, and the microscopic
examinations performed on slides of tissue sections. The NTP
requires examination of all organs and tissues, approximately 40
per animal.46 In some cases, multiple sectioning of an organ in
exposed and control groups may be necessary to obtain a truer
estimate of the incidence of neoplastic lesions, especially for
small lesions that may not be detected at necropsy.47 Although
diagnostic criteria have been established for most observable
lesions, it is not unusual for pathologists to disagree in their
judgment of lesions, especially those that are part of a
continuum of progressive change.48 After diagnoses by the study
pathologist, all NTP studies undergo an independent quality
assessment (QA) pathology review.49 This is followed by a
pathology working group review (typically eight to ten
pathologists) that seeks to resolve discrepancies in diagnoses
between the original and the QA pathologists.50 Studies that lack
multiple pathology evaluations may yield diagnostic data that
would not be generally accepted.
46

Department of Health and Human Services, National Toxicology
Program, http://ntp.niehs.nih.gov (last visited Dec. 15, 2006).
47
S.L. Eustis et al., The Utility of Multiple-section Sampling in the
Histopathological Evaluation of the Kidney for Carcinogenicity Studies, 22
TOXICOLOGIC PATHOLOGY 457, 457-72 (1994).
48
S.L. Eustis, The Sequential Development of Cancer: A Morphological
Perspective, 49 TOXICOLOGY LETTERS 267, 267-81 (1989).
49
G. A. Boorman et al., Quality Assurance in Pathology for Rodent
Carcinogenicity Studies, in HANDBOOK OF CARCINOGEN TESTING 345, 345-57
(H. Milman & E. Weisburger eds., 1985).
50
Id.
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In addition to statistical analyses described below, it should
be recognized that other factors may contribute to the
interpretation of tumor data, including: (1) the occurrence of
uncommon versus common tumors, (2) evidence of progression
of lesions, such as benign to malignant where it is appropriate to
combine,51 (3) tumor occurrence with reduced latency, (4)
multiplicity in a site-specific tumor response, (5) evidence of
metastases, and (6) supporting evidence of proliferative
preneoplastic lesions (lesions with high cell replication rates that
may progress to tumors) at the same organ site or detection of
the same lesion in the other sex or species. Because cancer
development is a multi-step process with a long time period
between exposure and manifestation of metastatic neoplasia,
evidence of enhanced disease progression (e.g., reduced latency,
tumor multiplicity, and metastasis) in an animal study is another
indication that the agent promotes cancer development.
B. Statistics
If mortality in a dose group is different from that of
controls, it is important that pair-wise comparisons and analyses
of trends be based on tumor rates that have been adjusted for
deaths occurring before the end of the study.52 The reason for
this survival-based adjustment is that if animals died early from
causes other than tumors at the organ site of interest, then those
animals would not have been on study long enough to provide a
full contribution of risk to that study group. Failure to adjust for
differences in survival will yield unreliable estimates of cancer
risk, and possible misinterpretations of a true site-specific effect.
Although comparisons between the concurrent control group
and the exposure groups are the most valid for identifying
chemically induced effects, comparisons with historical control
51

E. E. McConnell et al., Guidelines for Combining Neoplasms for
Evaluation of Rodent Carcinogenesis Studies, 76 J. NAT’L CANCER INST. 283,
283-89 (1986).
52
Joseph K. Haseman, Statistical Issues in the Design, Analysis and
Interpretation of Animal Carcinogenicity Studies, 58 ENVTL. HEALTH PERSP.
385, 385-92 (1984).
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data may also be helpful in interpreting treatment-related
effects.53 For meaningful comparisons, the conditions of the
current study must be similar to those in the historical database
and diagnostic criteria must be identical. Thus, comparisons
must be specific for the species, sex, and strain of animals, the
route of exposure, and the diet. For example, dietary factors
may influence animal survival, organ function, and spontaneous
or chemically induced tumor rates. Conflicting interpretations of
study findings may arise with improper use of historical
databases.
C. Mechanistic Considerations
Results from animal or in vitro studies that attempt to
determine the mode-of-action for disease induction (i.e.,
mechanistic studies) have been used to upgrade or downgrade
cancer risk classifications of agents that have inadequate or
limited evidence in humans.54 For example, based on
mechanistic data on early molecular and cellular events that
likely contribute to cancer outcome, IARC and NTP upgraded
ethylene
oxide55
and
2,3,7,8-tetrachlorodibenzo-p-dioxin
56
(TCDD) to “known human carcinogens.” In both cases, the
evidence of carcinogenicity was limited in humans and sufficient
53

Joseph K. Haseman, Use of Historical Control Data in
Carcinogenicity Studies in Rodents, 12 TOXICOLOGICAL PATHOLOGY 126,
126-35 (1984).
54
NAT’L TOXICOLOGY PROGRAM, supra note 10; 60 INT’L AGENCY FOR
RESEARCH ON CANCER, Ethylene Oxide, in IARC MONOGRAPHS ON THE
EVALUATION OF CARCINOGENIC RISKS TO HUMANS 73-159 (1994); 69 INT’L
AGENCY FOR RESEARCH ON CANCER, 2,3,7,8-Tetrachlorodibenzo-paradioxin, in IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS
TO HUMANS 33-343 (1997).
55
NAT’L TOXICOLOGY PROGRAM, supra note 10; 60 INT’L AGENCY FOR
RESEARCH ON CANCER, Ethylene Oxide, in IARC MONOGRAPHS ON THE
EVALUATION OF CARCINOGENIC RISKS TO HUMANS 73-159 (1994).
56
NAT’L TOXICOLOGY PROGRAM, supra note 10; 69 INT’L AGENCY FOR
RESEARCH ON CANCER, 2,3,7,8-Tetrachlorodibenzo-para-dioxin, in IARC
MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS 33343 (1997).
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in experimental animals. The upgrading of ethylene oxide was
based largely on the induction of chromosomal aberrations in
peripheral lymphocytes, micronuclei in bone marrow cells, and
hemoglobin adducts in exposed workers.57 For TCDD, the
upgrading was based on data demonstrating that the multi-site
carcinogenicity of this chemical in experimental animals was due
to a mechanism involving activation of the aryl hydrocarbon
receptor and studies showing that this receptor is highly
conserved across species and functions the same way in humans
as it does in experimental animals.58 Thus, even though human
epidemiological data alone were not sufficient to reach the
“known human carcinogen” classification category, these
authoritative bodies considered the combination of animal data
and mechanistic data sufficient to support the upgraded “weightof-evidence” conclusions. The term “weight-of-evidence” is
used by the EPA to reflect evaluations that are “based on the
combined strength and coherence of inferences appropriately
drawn from all of the available information.”59
Similarly, one should be very concerned of the potential
cancer risks for vinyl bromide (VBr) and vinyl fluoride (VF),
because they are structural analogs of vinyl chloride, a known
human carcinogen. Mechanistic data show that these three
chemicals are metabolized to DNA-reactive intermediates by
enzymes found in humans60 producing identical promutagenic
DNA adducts. Experimental carcinogenicity studies show that
these three chemicals induce multiple tumor types, including

57

NAT’L TOXICOLOGY PROGRAM, supra note 10; 60 INT’L AGENCY FOR
RESEARCH ON CANCER, Ethylene Oxide, in IARC MONOGRAPHS ON THE
EVALUATION OF CARCINOGENIC RISKS TO HUMANS 73-159 (1994).
58
NATIONAL TOXICOLOGY PROGRAM, supra note 10; INT’L AGENCY FOR
RESEARCH ON CANCER, 2,3,7,8-Tetrachlorodibenzo-para-dioxin, in 69 IARC
MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS 33343 (1997).
59
U.S. ENVTL. PROT. AGENCY, supra note 20, at 2-1.
60
F. Peter Guengerich et al., Role of Human Cytochrome P-450 IIE1 in
the Oxidation of Many Low Molecular Weight Cancer Suspects, 4 CHEMICAL
RESEARCH IN TOXICOLOGY 168, 168-79 (1991).
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angiosarcomas, in rats and mice.61 Because of these similarities,
it would be unethical to require human data on VBr or VF
before dealing with these chemicals as known human
carcinogens.
On the other hand, IARC downgraded the classification of
di(2-ethylhexyl)phthalate (DEHP) from “possibly” to “not
classifiable as to its carcinogenicity to humans.”62 The evidence
of the carcinogenicity of DEHP was concluded to be sufficient
in animals, based on increased incidences of liver tumors in rats
and mice, and inadequate in humans.63 The downgrading of the
animal cancer evidence was based on the panel’s acceptance of
the hypothesis that DEHP induces liver tumors in rats and mice
by a non-DNA-reactive mechanism involving an increase in the
number of peroxisomes (subcellular structures that contain
several oxidase enzymes). The tumor responses in rats and mice
were considered to be irrelevant to humans because peroxisome
proliferation had not been documented either in human
hepatocyte cultures exposed to DEHP or in the liver of exposed
non-human primates.64 However, peroxisome proliferation alone
has not been shown to provide a reasonable mechanistic
explanation for the different carcinogenic potencies of
peroxisome proliferators in the rat liver.65
Consequently, peroxisome proliferation may not be a reliable
marker for evaluating human cancer risk. Other mode-of-action
hypotheses for rodent liver tumor induction by peroxisome
proliferators have not been tested. Thus, the mechanistic basis

61

Ronald L. Melnick, Carcinogenicity and Mechanistic Insights on the
Behavior of Epoxides and Epoxide-forming Chemicals, 982 ANNALS N.Y.
ACADEMY OF SCIENCES 177, 177-89 (2002).
62
INT’L AGENCY FOR RESEARCH ON CANCER, supra note 18.
63
Id.
64
Id.
65
D. S. Marsman et al., Relationship of Hepatic Peroxisome
Proliferation and Replicative DNA Synthesis to the Hepatocarcinogenicity of
the Peroxisome Proliferators Di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in Rats, 48 CANCER
RESEARCH 6739, 6739-744 (1988).
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for the IARC decision to downgrade DEHP66 is not supported
by experimental evidence. Public health decisions that could lead
to unrestricted use and exposure to carcinogenic agents should
not rely on untested hypotheses.67
D. Site Concordance
Differences in the organ or tissue in which tumors arise in
animals and humans are one of the most contentious issues in
the evaluation of the human relevance of experimental
carcinogenicity data.68 This is largely due to the fact that the
etiologies or causes of most cancers are not known and the bases
for differences in species susceptibility are not fully
understood.69 There are several examples in which human
cancer sites correspond with one animal species, but not the
second species (e.g., hematopoietic cancers induced by benzene
in mice and humans, but not in rats) and there are also examples
of site correspondence among rats, mice, and humans.70
Although site correspondence may strengthen the animal-tohuman association, there are numerous reasons why that
correspondence should not be a requirement for human
relevance and causality. First, exposure factors might contribute
to differences in sites of tumor induction, including the route,
frequency, duration, intensity, as well as age at onset of
66
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Lornezo Tomatis, The IARC Monographs Program: Changing
Attitudes Towards Public Health, 8 INT’L J. OCCUPATIONAL ENVTL. HEALTH
144, 144-52 (2002).
68
Robert R. Maronpot et al., Relevance of Animal Carcinogenesis
Findings to Human Cancer Predictions and Prevention, Toxicologic
Pathology 32 Suppl. 1, 40-48 (2004).
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Carcinogenesis, Progress in Clinical & Biological Res. 395, 57-80 (1996);
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exposure.71 Exposure conditions are known to affect sites and
dose-response for tumor induction in experimental studies. If
gestational or early childhood exposure is important for tumor
induction, then studies of male workers would not be expected
to produce the same response as animal studies that include
exposures during these stages of development.
Second, there may not be an adequate human
epidemiological study on the agent or an epidemiological study
may not have detected a true increase in risk of certain cancers
in exposed human populations due to inadequate exposure
information, misclassifications, insufficient follow-up, and/or
inadequate study power.72
Third, human susceptibility to environmental carcinogens
varies for a large number of reasons including genetic factors,
health status, diet, lifestyle (e.g., smoking, alcohol
consumption), age, and other exposures (e.g., medications,
occupational experiences).73 Because cancer development is the
likely result of interactions among environmental factors and
individual susceptibility factors, differences in sites of tumor
induction among individuals are not unusual for known human
carcinogens. For example, although the lung is the most
common cancer site among cigarette smokers, many people do
not develop lung tumors but instead develop cancers of the
bladder, kidney, nasal cavity, lip, esophagus, or pancreas. In
some smokers no cancer is evident. Numerous host susceptibility
factors could account for lack of site correspondence among
individuals in exposed populations or between experimental
animals and humans.
Because of the much greater genetic diversity in humans
compared to strains of laboratory animals, the range of expected
71
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human response may include subgroups that are less, equal, or
more sensitive than the animal models used in the experimental
cancer studies. Unless a qualitative difference between animals
and humans is clearly shown to be the determinant of a speciesspecific cancer response, it is prudent to assume that a
carcinogenic effect in animals is a reliable indicator of potential
cancer risk in humans. This perspective has been endorsed by
major national and international public health agencies that
evaluate human cancer risks associated with exposures to
environmental and occupational agents.74
IV. ESTIMATING HUMAN CANCER RISK FROM ANIMAL DATA
Risk assessment provides a systematic approach for
characterizing the nature and probability of adverse effects (i.e.,
health risks) occurring in individuals or populations exposed to
hazardous agents and often serves as the basis for risk
management decisions on whether and to what extent human
exposure to such agents should be controlled. The National
Academy of Sciences/National Research Council (NAS/NRC)
developed guidelines for the conduct of risk assessments in the
federal government.75 The risk assessment paradigm developed
by the NAS/NRC consists of four parts: hazard identification,
dose-response assessment, exposure assessment, and risk
characterization.76
When adequate human data is not available, dose-response
data from studies in laboratory animals serve as the basis for
estimating risks in exposed humans.77 A quantitative risk
assessment requires conversion of animal doses to human

74
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equivalent doses.78 If a verified physiologically based
pharmacokinetic model is available for the specific agent, this
might be used to describe the internalized dose in humans by
replacing animal physiological and biochemical parameters in the
model with those specific for humans (e.g., breathing volumes,
organ sizes, cardiac output, metabolic rate constants, etc.).
Computer-based dosimetry models consist of a series of
mathematical equations that represent, in quantitative terms, the
complex biological processes that affect the absorption,
distribution, metabolism, and elimination of the agent in the
intact animal. These models can accommodate parameter values
that represent the range and distribution of activities that exist in
human populations. Reliable models can provide estimates of
tissue dose as a function of duration and frequency of exposure
to various environmental exposure levels.79 However, one must
be cautious of assumptions in models that have not been
validated because they could lead to inaccurate estimates of
tissue dose. If a verified dosimetry model is not available,
human equivalent exposures are typically obtained by scaling
animal doses to humans as a function of body surface area (i.e.,
body weight to the ¾ power).80 The assumption in this approach
that metabolic activities differ among species according to body
surface area may not be true.
The next step in the risk assessment process is to fit
empirical models (or mechanistic-based models if the mechanism
of the disease induction is known) to the dose and cancer
incidence data corrected for background and then to determine
which model provides the best fit to the dose-response data.
By extending the dose-response curve, it is possible to
estimate the cancer risk at human exposure levels, or to estimate
the exposure levels that are associated with specific risks (e.g.,
one per hundred, one per thousand, one per million). In their
most recent cancer risk assessment guidelines, the EPA
78
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recommends modeling dose-response data to determine the
effective dose associated with one percent (ED01) or 10 percent
(ED10) risk and the lower 95 percent limit on those dose
estimates (LED01 or LED10).81 From this point a straight line is
drawn to zero risk for mutagenic carcinogens or chemicals for
which the mode-of-action has not been characterized. Cancer
risks at lower exposure levels are estimated from the slope of
this line. These risks can then be compared to age, sex, and
race-dependent incidences of specific cancers in the U.S.
population reported in the Surveillance, Epidemiology, and End
Results (SEER) data set82 to determine the relative risk of
developing or dying from cancer due to a particular exposure.
Relative risk is the incidence of disease in an exposed population
divided by the incidence of that disease in the unexposed
population.83
For example, consider women working at a facility where
they are exposed until age 60 to a carcinogen at a level
associated with additional leukemia risk of 1.5 per thousand.
Since the probability of women in the general U.S. population
dying from leukemia by age 60 is 1.25 per thousand, then the
relative risk of dying from leukemia due to that exposure is 2.2.
The estimated incidence in the unexposed population is
1.25/1000, while the estimated incidence in the exposed
population is the background risk (1.25/1000) plus the additional
risk associated with exposure (1.5/1000). Relative risk equals
(0.00125 + 0.0015)/0.00125 = 2.2.
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CONCLUSION
Data from properly designed and evaluated studies in
experimental animals have been and continue to be reliable
sources of information for the identification of potential human
health hazards and the estimation of risks in exposed
populations. Properly designed animal studies must include: (1)
animal models that are sensitive to the endpoints under
investigation, (2) detailed characterization of the agent and the
administered doses, (3) challenging doses (MTD) and durations
of exposure (at least two years for rats and mice) that would
allow a reliable determination of whether or not the agent poses
a health hazard, (4) sufficient numbers of animals per dose
group to have adequate statistical power to detect a true effect,
(5) multiple dose groups to allow characterization of doseresponse relationships, (6) complete and peer-reviewed
histopathological evaluations, and (7) pair-wise comparisons and
analyses of trends based on survival-adjusted tumor rates.
Mechanistic information and pharmacokinetic models that have
been adequately tested may impact the characterization of doseresponse relationships. Until the etiology of environmentally
induced cancers and the basis for human susceptibility are better
understood, site correspondence should not be a requirement for
judging human relevance and causality.

